CA3011087A1 - Procedes de production d'agents therapeutiques anticancereux specifiques aux patients et procedes de traitement associes - Google Patents
Procedes de production d'agents therapeutiques anticancereux specifiques aux patients et procedes de traitement associes Download PDFInfo
- Publication number
- CA3011087A1 CA3011087A1 CA3011087A CA3011087A CA3011087A1 CA 3011087 A1 CA3011087 A1 CA 3011087A1 CA 3011087 A CA3011087 A CA 3011087A CA 3011087 A CA3011087 A CA 3011087A CA 3011087 A1 CA3011087 A1 CA 3011087A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- cell
- patient
- microfluidic device
- specific anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 3
- 238000002955 isolation Methods 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0652—Sorting or classification of particles or molecules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0819—Microarrays; Biochips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
Abstract
L'invention concerne un procédé de préparation d'un agent thérapeutique à base d'un anticorps, consistant à : (a) prendre un échantillon de cellules dissociées d'au moins un échantillon tumoral solide provenant d'un patient ; (b) charger l'échantillon de cellules dissociées dans un dispositif microfluidique présentant une région d'écoulement et au moins une zone d'isolement en communication fluidique avec la région d'écoulement ; (c) déplacer au moins un lymphocyte B de l'échantillon de cellules dissociées dans au moins une zone d'isolement dans le dispositif microfluidique, ce qui permet d'obtenir au moins un lymphocyte B isolé ; et (d) utiliser le dispositif microfluidique pour identifier au moins un lymphocyte B qui produit des anticorps capables de se lier à des cellules cancéreuses. Les cellules cancéreuses peuvent être les cellules cancéreuses propres au patient. L'invention concerne également des procédés de traitement de patients, des procédés de marquage ou de détection d'un cancer, des cellules NK ou T modifiées comprenant des anticorps ou des fragments correspondants et des constructions d'anticorps modifiées.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662279341P | 2016-01-15 | 2016-01-15 | |
US62/279,341 | 2016-01-15 | ||
US201662411690P | 2016-10-23 | 2016-10-23 | |
US62/411,690 | 2016-10-23 | ||
US201662412092P | 2016-10-24 | 2016-10-24 | |
US62/412,092 | 2016-10-24 | ||
PCT/US2017/013483 WO2017123978A1 (fr) | 2016-01-15 | 2017-01-13 | Procédés de production d'agents thérapeutiques anticancéreux spécifiques aux patients et procédés de traitement associés |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3011087A1 true CA3011087A1 (fr) | 2017-07-20 |
Family
ID=57960827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3011087A Pending CA3011087A1 (fr) | 2016-01-15 | 2017-01-13 | Procedes de production d'agents therapeutiques anticancereux specifiques aux patients et procedes de traitement associes |
Country Status (10)
Country | Link |
---|---|
US (2) | US10712344B2 (fr) |
EP (2) | EP3402814B1 (fr) |
JP (3) | JP6902548B2 (fr) |
KR (1) | KR102512608B1 (fr) |
CN (1) | CN109952313B (fr) |
AU (2) | AU2017207450B2 (fr) |
CA (1) | CA3011087A1 (fr) |
SG (1) | SG11201805592RA (fr) |
TW (2) | TWI756199B (fr) |
WO (1) | WO2017123978A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014DN06624A (fr) | 2005-10-18 | 2015-07-10 | Univ Colorado | |
AU2009246876B2 (en) | 2008-05-16 | 2015-04-02 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
DK2966084T3 (en) | 2008-08-28 | 2018-08-06 | Taiga Biotechnologies Inc | MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC |
SG11201500429QA (en) | 2012-07-20 | 2015-03-30 | Taiga Biotechnologies Inc | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
EP2906269B1 (fr) | 2012-10-11 | 2018-01-03 | Magnolia Medical Technologies, Inc. | Système d'administration d'un fluide à un patient en réduisant la contamination |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
WO2017117521A1 (fr) | 2015-12-31 | 2017-07-06 | Berkeley Lights, Inc. | Cellules infiltrant les tumeurs, modifiées pour exprimer un polypeptide pro-inflammatoire |
EP3402814B1 (fr) | 2016-01-15 | 2021-04-21 | Berkeley Lights, Inc. | Procédés de production d'agents thérapeutiques anticancéreux spécifiques aux patients et procédés de traitement associés |
WO2017160991A1 (fr) | 2016-03-16 | 2017-09-21 | Lavieu Gregory G | Procédés, systèmes et dispositifs pour la sélection et la génération de clones résultant d'une édition génomique |
KR20190092472A (ko) | 2016-12-02 | 2019-08-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | 나노입자 제제 |
WO2018111765A1 (fr) | 2016-12-12 | 2018-06-21 | xCella Biosciences, Inc. | Procédés et systèmes de criblage à l'aide de réseaux microcapillaires |
WO2018126205A1 (fr) | 2016-12-30 | 2018-07-05 | The Regents Of The University Of California | Procédés de sélection et de génération de lymphocytes t modifiés par le génome |
JP6992079B2 (ja) | 2017-04-23 | 2022-01-13 | ヒューレット-パッカード デベロップメント カンパニー エル.ピー. | 粒子分離 |
EP3635112A2 (fr) | 2017-06-06 | 2020-04-15 | Zymergen, Inc. | Plate-forme d'ingénierie génomique htp permettant d'améliorer les souches fongiques |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
CN115028739A (zh) * | 2017-08-03 | 2022-09-09 | 泰加生物工艺学公司 | 用于治疗黑素瘤的方法和组合物 |
CN116250868A (zh) | 2017-09-12 | 2023-06-13 | 木兰医药技术股份有限公司 | 流体控制装置及其使用方法 |
US10871440B2 (en) | 2017-12-23 | 2020-12-22 | Lumacyte, LLC | Microfluidic chip device for optical force measurements and cell imaging using microfluidic chip configuration and dynamics |
WO2019232473A2 (fr) * | 2018-05-31 | 2019-12-05 | Berkeley Lights, Inc. | Détection et caractérisation automatiques de micro-objets dans des dispositifs microfluidiques |
KR20210018219A (ko) | 2018-06-06 | 2021-02-17 | 지머젠 인코포레이티드 | 발효 및 생산 중 곰팡이 형태를 제어하기 위한 신호 전달에 포함된 유전자의 조작 |
EP3938108B1 (fr) | 2019-03-11 | 2023-08-02 | Magnolia Medical Technologies, Inc. | Dispositifs de régulation de fluide |
CN111808815A (zh) * | 2019-04-11 | 2020-10-23 | 北京基石生命科技有限公司 | 一种胃癌实体瘤原代细胞的培养方法 |
WO2020233503A1 (fr) * | 2019-05-17 | 2020-11-26 | University Of Macau | Procédé de détection |
EP3990285A4 (fr) | 2019-06-25 | 2023-04-19 | Hewlett-Packard Development Company, L.P. | Structures moulées pourvues de canaux |
US11335636B2 (en) * | 2019-10-29 | 2022-05-17 | Hefei Reliance Memory Limited | Gradual breakdown memory cell having multiple different dielectrics |
WO2021102308A1 (fr) * | 2019-11-21 | 2021-05-27 | Emulate Inc. | Dispositifs microfluidiques produisant des anticorps |
JPWO2022004620A1 (fr) * | 2020-06-29 | 2022-01-06 | ||
JP7197538B2 (ja) * | 2020-07-03 | 2022-12-27 | タイガ バイオテクノロジーズ,インク. | メラノーマの処置のための方法および組成物 |
US11479779B2 (en) | 2020-07-31 | 2022-10-25 | Zymergen Inc. | Systems and methods for high-throughput automated strain generation for non-sporulating fungi |
US20220304664A1 (en) * | 2021-03-26 | 2022-09-29 | Jeremy Hammer | Apparatus and methods for bodily fluid sample collection |
US11763647B2 (en) * | 2021-08-16 | 2023-09-19 | City University Of Hong Kong | Multimode haptic patch and multimodal haptic feedback interface |
CN113996355B (zh) * | 2021-10-28 | 2023-06-06 | 上海浚真生命科学有限公司 | 取样装置 |
WO2023133895A1 (fr) * | 2022-01-17 | 2023-07-20 | 深圳华大生命科学研究院 | Procédé d'obtention d'informations sur un nano-anticorps reconnaissant spécifiquement un antigène |
CN114574587B (zh) * | 2022-04-06 | 2022-12-02 | 北京莱盟君泰国际医疗技术开发有限公司 | 一种用于结直肠癌检测的标记物组合物及其应用 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2618497B2 (ja) * | 1989-10-03 | 1997-06-11 | 鐘淵化学工業株式会社 | 腫瘍障害細胞誘導剤および腫瘍障害細胞誘導デバイス |
CA2255599C (fr) | 1996-04-25 | 2006-09-05 | Bioarray Solutions, Llc | Assemblage electrocinetique de particules proches des surfaces regule par la lumiere |
US6294063B1 (en) | 1999-02-12 | 2001-09-25 | Board Of Regents, The University Of Texas System | Method and apparatus for programmable fluidic processing |
US6942776B2 (en) | 1999-05-18 | 2005-09-13 | Silicon Biosystems S.R.L. | Method and apparatus for the manipulation of particles by means of dielectrophoresis |
US7223364B1 (en) | 1999-07-07 | 2007-05-29 | 3M Innovative Properties Company | Detection article having fluid control film |
WO2001096025A2 (fr) | 2000-06-14 | 2001-12-20 | Board Of Regents, The University Of Texas System | Systeme et procedes d'analyse de sous-populations de cellules |
US20030007894A1 (en) | 2001-04-27 | 2003-01-09 | Genoptix | Methods and apparatus for use of optical forces for identification, characterization and/or sorting of particles |
ITTO20010411A1 (it) | 2001-05-02 | 2002-11-02 | Silicon Biosystems S R L | Metodo e dispositivo per l'esecuzione di test e saggi ad alta processivita' ed alto valore biologico su cellule e/o composti. |
US7312085B2 (en) | 2002-04-01 | 2007-12-25 | Fluidigm Corporation | Microfluidic particle-analysis systems |
US6958132B2 (en) | 2002-05-31 | 2005-10-25 | The Regents Of The University Of California | Systems and methods for optical actuation of microfluidics based on opto-electrowetting |
US7790443B2 (en) | 2002-08-27 | 2010-09-07 | Vanderbilt University | Bioreactors with substance injection capacity |
EP1561107A1 (fr) | 2002-11-13 | 2005-08-10 | Micromet AG | Procede d'identification de cellules b specifiques d'un antigene |
WO2004065618A2 (fr) | 2003-01-16 | 2004-08-05 | Thermogenic Imaging | Procedes et dispositifs permettant de controler le metabolisme cellulaire dans des chambres de retenue de cellules |
EP2340890B1 (fr) | 2003-04-03 | 2016-10-19 | Fluidigm Corporation | Procédé pour réaliser PCR numérique |
JP4328168B2 (ja) | 2003-10-02 | 2009-09-09 | ソニー株式会社 | 毛細管現象を利用する物質間の相互作用検出部と該検出部を用いる方法及びバイオアッセイ用基板 |
WO2005053729A1 (fr) | 2003-11-26 | 2005-06-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Facteur de cellule souche pour l'induction de la migration de cellule souche neuronale vers des zones de blessure neurologique |
US7425253B2 (en) | 2004-01-29 | 2008-09-16 | Massachusetts Institute Of Technology | Microscale sorting cytometer |
US8765454B2 (en) | 2004-02-18 | 2014-07-01 | Xiaochuan Zhou | Fluidic devices and methods for multiplex chemical and biochemical reactions |
WO2005100541A2 (fr) | 2004-04-12 | 2005-10-27 | The Regents Of The University Of California | Pinces optoelectroniques pour la manipulation de microparticules et de cellules |
US20060091015A1 (en) | 2004-11-01 | 2006-05-04 | Applera Corporation | Surface modification for non-specific adsorption of biological material |
WO2007008609A2 (fr) | 2005-07-07 | 2007-01-18 | The Regents Of The University Of California | Methodes et dispositif pour reseau de culture cellulaire |
AU2006283518A1 (en) | 2005-08-19 | 2007-03-01 | The Regents Of The University Of California | Microfluidic methods for diagnostics and cellular analysis |
US8449837B2 (en) | 2005-10-11 | 2013-05-28 | The Johns Hopkins University | Microfluidic device for high-throughput cellular gradient and dose response studies |
WO2007102839A2 (fr) | 2005-10-27 | 2007-09-13 | Applera Corporation | Separation optoelectronique de biomolecules |
WO2007092713A2 (fr) * | 2006-02-02 | 2007-08-16 | Trustees Of The University Of Pennsylvania | Système microfluidique et procédé d'analyse de l'expression génique dans des échantillons contenant des cellules et procédé de détection d'une maladie |
US8124015B2 (en) | 2006-02-03 | 2012-02-28 | Institute For Systems Biology | Multiplexed, microfluidic molecular assay device and assay method |
CA2674239C (fr) * | 2006-12-28 | 2018-01-23 | Centocor Ortho Biotech Inc. | Procedes et vecteurs de generation d'immunoglobulines asialylees |
US8157434B2 (en) | 2007-01-19 | 2012-04-17 | Fluidigm Corporation | High efficiency and high precision microfluidic devices and methods |
WO2008091848A2 (fr) | 2007-01-22 | 2008-07-31 | Advanced Liquid Logic, Inc. | Chargement de fluide assisté en surface et distribution de gouttelette |
WO2008119066A1 (fr) | 2007-03-28 | 2008-10-02 | The Regents Of The University Of California | Brucelles optoélectroniques à champ latéral simple face et à base de phototransistor |
EP2150350B1 (fr) | 2007-05-24 | 2012-04-25 | The Regents of the University of California | Dispositifs fluidiques intégrés à tri magnétique |
US20090068170A1 (en) | 2007-07-13 | 2009-03-12 | President And Fellows Of Harvard College | Droplet-based selection |
CN101910415B (zh) | 2007-11-07 | 2015-02-25 | 不列颠哥伦比亚大学 | 微流体装置及其使用方法 |
WO2009151505A1 (fr) * | 2008-04-11 | 2009-12-17 | China Molecular, Ltd. | Dispositifs et procédés utilisables pour la production d'immunoglobulines |
EP2279238A2 (fr) | 2008-04-21 | 2011-02-02 | Cell Kinetics, Ltd. | Supports plats de cellules avec pièges à cellules |
CN101275114A (zh) | 2008-04-22 | 2008-10-01 | 北京大学 | 一种微流细胞培养阵列及其应用 |
GB2464300A (en) | 2008-10-10 | 2010-04-14 | Univ Dublin City | Microfluidic multiplexed cellular and molecular analysis device and method |
US20110236393A1 (en) * | 2008-11-04 | 2011-09-29 | Duke University | Monoclonal antibody production in b cells and uses therof |
US20120045827A1 (en) | 2009-03-09 | 2012-02-23 | Biofactura, Inc. | Separation of antigen-specific memory b cells with a conjugated biopolymer surface |
CN102449163A (zh) | 2009-04-03 | 2012-05-09 | 加利福尼亚大学董事会 | 分选细胞和其它生物微粒的方法和装置 |
US20100273681A1 (en) | 2009-04-27 | 2010-10-28 | Wisconsin Alumni Research Foundation | Combinatorial chemistry reaction cell with optical tweezers |
GB0909923D0 (en) | 2009-06-09 | 2009-07-22 | Oxford Gene Tech Ip Ltd | Picowell capture devices for analysing single cells or other particles |
JP2011000079A (ja) | 2009-06-19 | 2011-01-06 | Univ Of Tokyo | 粒子を操作する方法及びマイクロ流体装置 |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
US20130118905A1 (en) | 2010-05-26 | 2013-05-16 | Tosoh Corporation | Biological sample immobilizing apparatus |
CN101947124B (zh) | 2010-06-25 | 2012-07-04 | 博奥生物有限公司 | 一种集成式微流控芯片装置及其使用方法 |
US20130115606A1 (en) | 2010-07-07 | 2013-05-09 | The University Of British Columbia | System and method for microfluidic cell culture |
US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
US9533306B2 (en) | 2010-08-02 | 2017-01-03 | The Regents Of The University Of California | Single sided continuous optoelectrowetting (SCEOW) device for droplet manipulation with light patterns |
EP2616551B1 (fr) | 2010-09-14 | 2020-08-19 | The Regents of The University of California | Procédé pour isoler des cellules d'une solution hétérogène en utilisant des pièges à tourbillon microfluidique |
CN105842435B (zh) | 2010-12-03 | 2019-03-05 | 塞普莱有限公司 | 细胞功能的微分析 |
WO2012072823A1 (fr) | 2010-12-03 | 2012-06-07 | Mindseeds Laboratories Srl | Criblage rapide d'anticorps monoclonaux |
CN103889556A (zh) | 2011-01-06 | 2014-06-25 | Gpb科学有限责任公司 | 在引入亲和性和大小两者的微流体芯片上的循环肿瘤细胞捕获 |
SG192931A1 (en) | 2011-02-28 | 2013-09-30 | Harvard College | Cell culture system |
WO2012162779A1 (fr) | 2011-05-27 | 2012-12-06 | The University Of British Columbia | Appareil microfluidique de piégeage et d'essai cellulaires pour analyse à haut rendement |
US9227200B2 (en) | 2011-06-03 | 2016-01-05 | The Regents Of The University Of California | Microfluidic devices with flexible optically transparent electrodes |
WO2013019491A1 (fr) | 2011-08-01 | 2013-02-07 | Denovo Sciences | Système de capture de cellules et procédé d'utilisation |
US9050593B2 (en) | 2011-11-23 | 2015-06-09 | Wisconsin Alumni Research Foundation | Self-loading microfluidic device and methods of use |
US20150004253A1 (en) * | 2012-01-20 | 2015-01-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method for the prognosis of survival time of a patient suffering from a solid cancer |
CN105074003A (zh) * | 2012-09-13 | 2015-11-18 | 哈佛大学校长及研究员协会 | 实体组织的单细胞中的多元分析测量的方法 |
US9857333B2 (en) | 2012-10-31 | 2018-01-02 | Berkeley Lights, Inc. | Pens for biological micro-objects |
US9403172B2 (en) | 2012-11-08 | 2016-08-02 | Berkeley Lights, Inc. | Circuit based optoelectronic tweezers |
CN105492621A (zh) | 2013-03-28 | 2016-04-13 | 英属哥伦比亚大学 | 微流控装置及其在多细胞分泌检测中的使用方法 |
US9889445B2 (en) * | 2013-10-22 | 2018-02-13 | Berkeley Lights, Inc. | Micro-fluidic devices for assaying biological activity |
US10010882B2 (en) * | 2013-10-22 | 2018-07-03 | Berkeley Lights, Inc. | Microfluidic devices having isolation pens and methods of testing biological micro-objects with same |
US9617145B2 (en) | 2013-10-22 | 2017-04-11 | Berkeley Lights, Inc. | Exporting a selected group of micro-objects from a micro-fluidic device |
US20150306598A1 (en) | 2014-04-25 | 2015-10-29 | Berkeley Lights, Inc. | DEP Force Control And Electrowetting Control In Different Sections Of The Same Microfluidic Apparatus |
US20150306599A1 (en) | 2014-04-25 | 2015-10-29 | Berkeley Lights, Inc. | Providing DEP Manipulation Devices And Controllable Electrowetting Devices In The Same Microfluidic Apparatus |
AU2015249294B2 (en) | 2014-04-25 | 2020-02-27 | Berkeley Lights, Inc. | Providing DEP manipulation devices and controllable electrowetting devices in the same microfluidic apparatus |
US20150352547A1 (en) | 2014-06-06 | 2015-12-10 | Berkeley Lights, Inc. | Isolating Microfluidic Structures and Trapping Bubbles |
CN104293666B (zh) * | 2014-09-11 | 2016-06-22 | 大连理工大学 | 两种不同单细胞之间相互作用的微流控芯片装置 |
WO2016065470A1 (fr) | 2014-10-27 | 2016-05-06 | The Governing Council Of The University Of Toronto | Dispositif microfluidique pour dosages à base de cellules |
SG11201704558QA (en) | 2014-12-08 | 2017-07-28 | Berkeley Lights Inc | Microfluidic device comprising lateral/vertical transistor structures and process of making and using same |
AU2015360611B2 (en) | 2014-12-10 | 2021-04-01 | Berkeley Lights, Inc. | Systems for operating electrokinetic devices |
US9744533B2 (en) | 2014-12-10 | 2017-08-29 | Berkeley Lights, Inc. | Movement and selection of micro-objects in a microfluidic apparatus |
SG11201708429WA (en) | 2015-04-22 | 2017-11-29 | Berkeley Lights Inc | Microfluidic cell culture |
JP6964590B2 (ja) | 2015-12-30 | 2021-11-10 | バークレー ライツ,インコーポレイテッド | 光学的に駆動される対流及び変位のマイクロ流体デバイス、そのキット及び方法 |
EP3402814B1 (fr) | 2016-01-15 | 2021-04-21 | Berkeley Lights, Inc. | Procédés de production d'agents thérapeutiques anticancéreux spécifiques aux patients et procédés de traitement associés |
KR102614839B1 (ko) | 2016-04-15 | 2023-12-15 | 버클리 라잇츠, 인크. | 펜 내 분석들을 위한 방법들, 시스템들 및 키트들 |
CN115678773A (zh) | 2016-05-26 | 2023-02-03 | 伯克利之光生命科技公司 | 共价修饰的表面、试剂盒及制备方法和用途 |
-
2017
- 2017-01-13 EP EP17702984.0A patent/EP3402814B1/fr active Active
- 2017-01-13 CN CN201780015039.2A patent/CN109952313B/zh active Active
- 2017-01-13 AU AU2017207450A patent/AU2017207450B2/en active Active
- 2017-01-13 TW TW106101314A patent/TWI756199B/zh active
- 2017-01-13 CA CA3011087A patent/CA3011087A1/fr active Pending
- 2017-01-13 EP EP21169005.2A patent/EP3889176A1/fr active Pending
- 2017-01-13 JP JP2018536394A patent/JP6902548B2/ja active Active
- 2017-01-13 SG SG11201805592RA patent/SG11201805592RA/en unknown
- 2017-01-13 TW TW111105644A patent/TWI821913B/zh active
- 2017-01-13 KR KR1020187023525A patent/KR102512608B1/ko active IP Right Grant
- 2017-01-13 WO PCT/US2017/013483 patent/WO2017123978A1/fr active Application Filing
- 2017-01-13 US US15/406,289 patent/US10712344B2/en active Active
-
2020
- 2020-06-04 US US16/892,642 patent/US11971409B2/en active Active
-
2021
- 2021-06-21 JP JP2021102173A patent/JP2021153594A/ja active Pending
-
2022
- 2022-01-27 AU AU2022200495A patent/AU2022200495A1/en active Pending
-
2023
- 2023-03-22 JP JP2023046052A patent/JP2023082046A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3402814A1 (fr) | 2018-11-21 |
JP2019511454A (ja) | 2019-04-25 |
US10712344B2 (en) | 2020-07-14 |
AU2017207450B2 (en) | 2021-11-04 |
CN109952313A (zh) | 2019-06-28 |
AU2017207450A1 (en) | 2018-07-19 |
EP3402814B1 (fr) | 2021-04-21 |
US20200400669A1 (en) | 2020-12-24 |
TWI821913B (zh) | 2023-11-11 |
TW202221321A (zh) | 2022-06-01 |
TW201734207A (zh) | 2017-10-01 |
WO2017123978A1 (fr) | 2017-07-20 |
KR102512608B1 (ko) | 2023-03-22 |
US20170276679A1 (en) | 2017-09-28 |
EP3889176A1 (fr) | 2021-10-06 |
SG11201805592RA (en) | 2018-07-30 |
TWI756199B (zh) | 2022-03-01 |
KR20180101548A (ko) | 2018-09-12 |
CN109952313B (zh) | 2023-12-19 |
JP2021153594A (ja) | 2021-10-07 |
JP2023082046A (ja) | 2023-06-13 |
JP6902548B2 (ja) | 2021-07-14 |
US11971409B2 (en) | 2024-04-30 |
AU2022200495A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3011087A1 (fr) | Procedes de production d'agents therapeutiques anticancereux specifiques aux patients et procedes de traitement associes | |
MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
WO2018098365A3 (fr) | Compositions et méthodes de reprogrammation de tcr au moyen de protéines de fusion | |
MY193112A (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment | |
WO2019222275A3 (fr) | Compositions et procédés de reprogrammation de tcr utilisant des protéines de fusion inductibles | |
MX2020012286A (es) | Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t. | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
MX2019010958A (es) | Metodos de tratamiento de tumores. | |
EA201891966A1 (ru) | Молекулы, связывающие bcma, и способы их применения | |
MX2019005125A (es) | Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. | |
MX2017015260A (es) | Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer. | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
BR112017019785A2 (pt) | anticorpos terapêuticos e seus usos | |
PH12018502250A1 (en) | Cancer immunotherapy by immune activation for immune modulation via globo series antigens | |
WO2016160620A3 (fr) | Lymphocytes t car pour le traitement des tumeurs solides exprimant b7-h4 | |
NZ591137A (en) | Methods and systems for predicting response of cells to a therapeutic agent | |
WO2003106692A3 (fr) | Procedes d'identification d'allo-antigenes et leur utilisation dans la therapie anticancereuse et la transplantation | |
MX2018010508A (es) | Preparaciones mejoradas de celulas progenitoras hepaticas adultas. | |
MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
WO2018081625A3 (fr) | Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques | |
MX2021002241A (es) | Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1). | |
MX2013011354A (es) | Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno. | |
MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
WO2019118793A3 (fr) | Cellules d'inhibition de tumeur spécifique à un sujet et leur utilisation | |
WO2007144046A3 (fr) | Agent de traitement de pathologies malignes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20220111 |
|
EEER | Examination request |
Effective date: 20220111 |
|
EEER | Examination request |
Effective date: 20220111 |
|
EEER | Examination request |
Effective date: 20220111 |
|
EEER | Examination request |
Effective date: 20220111 |